Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1353-1360
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1353
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1353
Table 1 Baseline characteristics of study cohort n (%)
| Characteristic | Data | |
| Sex | Male | 28 (71.8) |
| Female | 11 (28.2) | |
| Age (yr) | 58.6 (range: 45.8-72.3) | |
| Immunosuppression | Cyclosporine | 19 (48.7) |
| Tacrolimus | 18 (46.2) | |
| Sirolimus | 1 (2.6) | |
| Everolimus | 1 (2.6) | |
| Mycophenolate mofetil | 21 (53.8) | |
| Liver histology | F0-2 | 7 (17.9) |
| F3 | 15 (38.5) | |
| F4 | 17 (43.6) | |
| Liver function, CTP | A | 17 (43.6) |
| B | 2 (5.1) | |
| Risk factors | Interferon-experienced | 29 (74.4) |
| History of HCC | 26 (66.7) | |
| HCV genotype | 1 | 24 (61.5) |
| 2 | 1 (2.6) | |
| 3 | 13 (33.3) | |
| 4 | 1 (2.6) | |
- Citation: Rupp C, Hippchen T, Neuberger M, Sauer P, Pfeiffenberger J, Stremmel W, Gotthardt DN, Mehrabi A, Weiss KH. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J Gastroenterol 2018; 24(12): 1353-1360
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1353.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1353